ONCY - Latest News

Oncolytics Biotech Inc. (ONCY), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $49.2M. Beta to the broader market is 1.16.

The article list below shows the most recent ONCY headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ONCY Headlines

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment

globenewswire.com - Oct 14, 2026

Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

globenewswire.com - Oct 12, 2026

New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U. S.

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

globenewswire.com - Sep 29, 2026

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc.

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

globenewswire.com - Sep 28, 2026

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

globenewswire.com - Sep 10, 2026

Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer mode

How News Affects ONCY Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ONCY's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ONCY news questions

What is the latest ONCY news headline?

The most recent ONCY headline (Oct 14, 2026) is "Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ONCY news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ONCY news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ONCY options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.